CA3124790A1 - Transferrin receptor-binding molecules, conjugates thereof and their uses - Google Patents

Transferrin receptor-binding molecules, conjugates thereof and their uses Download PDF

Info

Publication number
CA3124790A1
CA3124790A1 CA3124790A CA3124790A CA3124790A1 CA 3124790 A1 CA3124790 A1 CA 3124790A1 CA 3124790 A CA3124790 A CA 3124790A CA 3124790 A CA3124790 A CA 3124790A CA 3124790 A1 CA3124790 A1 CA 3124790A1
Authority
CA
Canada
Prior art keywords
vhh
seq
nos
molecule
tfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3124790A
Other languages
English (en)
French (fr)
Inventor
Romy COHEN
Marion David
Michel Khrestchatisky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aix Marseille Universite
Centre National de la Recherche Scientifique CNRS
Vect Horus
Original Assignee
Aix Marseille Universite
Centre National de la Recherche Scientifique CNRS
Vect Horus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aix Marseille Universite, Centre National de la Recherche Scientifique CNRS, Vect Horus filed Critical Aix Marseille Universite
Publication of CA3124790A1 publication Critical patent/CA3124790A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA3124790A 2019-01-09 2020-01-08 Transferrin receptor-binding molecules, conjugates thereof and their uses Pending CA3124790A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19305031.7 2019-01-09
EP19305031 2019-01-09
PCT/EP2020/050318 WO2020144233A1 (en) 2019-01-09 2020-01-08 Transferrin receptor-binding molecules, conjugates thereof and their uses

Publications (1)

Publication Number Publication Date
CA3124790A1 true CA3124790A1 (en) 2020-07-16

Family

ID=65236972

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3124790A Pending CA3124790A1 (en) 2019-01-09 2020-01-08 Transferrin receptor-binding molecules, conjugates thereof and their uses

Country Status (9)

Country Link
US (1) US12152317B2 (https=)
EP (1) EP3908608A1 (https=)
JP (1) JP7599425B2 (https=)
CN (1) CN113474369B (https=)
AU (1) AU2020206593B2 (https=)
BR (1) BR112021013559A2 (https=)
CA (1) CA3124790A1 (https=)
EA (1) EA202191893A1 (https=)
WO (1) WO2020144233A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12258597B2 (en) 2018-02-07 2025-03-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
US20240391967A1 (en) * 2020-12-02 2024-11-28 University Health Network Methods and uses for ndfip1 fusion polypeptides in treating neurodegenerative diseases, brain and/or traumatic and non-traumatic spinal cord injuries, and/or optic neuropathies
MX2024005968A (es) * 2021-11-19 2024-08-06 Japan Chem Res Peptido que tiene afinidad por el receptor de transferrina humano.
CN117377487B (zh) 2021-12-02 2024-11-22 领诺(上海)医药科技有限公司 转铁蛋白结合抗体及其应用
US11939391B2 (en) * 2021-12-06 2024-03-26 MedAbome, Inc. Anti-TfR1 antibody MAb11-22.1 conjugates for cancer treatment
WO2023128702A1 (ko) * 2021-12-31 2023-07-06 주식회사 아임뉴런 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
CN119301262A (zh) 2022-04-01 2025-01-10 武田药品工业株式会社 用于具有cns表现的疾病的基因疗法
EP4526344A1 (en) * 2022-05-16 2025-03-26 Denali Therapeutics Inc. Transferrin receptor-binding domains and proteins comprising the same
CN120659627A (zh) * 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
KR20250111123A (ko) 2022-11-23 2025-07-22 키2브레인 에이비 Vhh 항체 및 이의 용도
US20260116990A1 (en) 2022-11-23 2026-04-30 Key2Brain Ab Vhh antibodies and uses thereof
AU2023404617A1 (en) * 2022-12-02 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-tfr1 antibodies and uses thereof
TW202436352A (zh) * 2023-02-07 2024-09-16 日商Ｊｃｒ製藥股份有限公司 人類運鐵蛋白受體親和性肽
CN116179607A (zh) * 2023-03-27 2023-05-30 迦进生物医药(上海)有限公司 一种human TfR2高表达的稳转细胞株及其构建方法和应用
CN116121306A (zh) * 2023-03-27 2023-05-16 迦进生物医药(上海)有限公司 一种human TfR1高表达的稳转细胞株及其构建方法和应用
AU2024243709A1 (en) 2023-04-03 2025-11-06 Katholieke Universiteit Leuven Blood-brain barrier crossing antibodies
CN121794291A (zh) 2023-06-22 2026-04-03 维克塔-霍洛斯公司 转铁蛋白受体结合分子、其偶联物及其用于预防或治疗肌肉疾病的用途
EP4731658A1 (en) 2023-06-22 2026-04-29 Vect-Horus Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat nervous system diseases
EP4480964A1 (en) 2023-06-22 2024-12-25 Vect-Horus Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat muscular diseases
EP4480965A1 (en) 2023-06-22 2024-12-25 Vect-Horus Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat cns diseases
CN121773136A (zh) * 2023-07-04 2026-03-31 北京星奇原生物科技有限公司 抗-TfR1抗体及其用途
WO2025042711A1 (en) 2023-08-18 2025-02-27 Eli Lilly And Company Engineered transferrin receptor binding peptides as well as methods of making and using the same
US20250064958A1 (en) * 2023-08-22 2025-02-27 Eli Lilly And Company AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENTS
WO2025194170A1 (en) * 2024-03-15 2025-09-18 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted internalization and degradation of immune-related membrane proteins
WO2025194171A1 (en) * 2024-03-15 2025-09-18 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted internalization and degradation of g protein-coupled receptors
WO2025207959A1 (en) * 2024-03-27 2025-10-02 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
WO2025207946A1 (en) * 2024-03-28 2025-10-02 Genzyme Corporation Polypeptides binding to a specific epitope of the transferrin receptor 1
WO2025226642A1 (en) 2024-04-25 2025-10-30 Eli Lilly And Company Lipid nano delivery particles for targeted transport of nucleic acids and methods of making and using the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2441903C (en) * 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
EP2008666A1 (en) * 2007-06-29 2008-12-31 Institut Pasteur Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications
EP2207568B1 (en) 2007-11-16 2017-05-31 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
FR2959229B1 (fr) 2010-04-21 2013-01-18 Vect Horus Derives peptidiques, leur preparation et leurs utilisations
CA2813411C (en) * 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CA2818173C (en) 2010-11-30 2022-05-03 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
WO2013177062A2 (en) 2012-05-21 2013-11-28 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
WO2014089209A2 (en) * 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
CN105102478A (zh) * 2013-01-30 2015-11-25 弗拉芒区生物技术研究所 用于筛选和药物发现目的的新型嵌合多肽
EP2899208A1 (en) * 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
NZ724869A (en) * 2014-03-06 2022-07-01 Nat Res Council Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
EP3218411B1 (en) 2014-11-14 2022-01-12 Ossianix, Inc. Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use
EA039366B1 (ru) 2015-06-24 2022-01-19 Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
EP3494216B1 (en) 2016-08-06 2025-10-15 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use

Also Published As

Publication number Publication date
WO2020144233A1 (en) 2020-07-16
CN113474369A (zh) 2021-10-01
EP3908608A1 (en) 2021-11-17
JP7599425B2 (ja) 2024-12-13
BR112021013559A2 (pt) 2021-09-21
JP2022518392A (ja) 2022-03-15
US12152317B2 (en) 2024-11-26
US20220090050A1 (en) 2022-03-24
CN113474369B (zh) 2024-09-03
EA202191893A1 (ru) 2021-12-02
AU2020206593B2 (en) 2026-02-05
AU2020206593A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
AU2020206593B2 (en) Transferrin receptor-binding molecules, conjugates thereof and their uses
JP6541237B2 (ja) インスリン様成長因子１受容体特異的抗体及びそれらの使用
US20230414780A1 (en) Transferrin receptor-binding molecules, conjugates thereof and their uses
JP2017514456A (ja) インスリン様成長因子１受容体特異的抗体及びそれらの使用
JP2017513461A (ja) インスリン様成長因子１受容体特異的抗体及びそれらの使用
AU2017293450A1 (en) Humanized antibodies transmigrating the blood-brain barrier and uses thereof
US20260062480A1 (en) Human blood-brain barrier targeting antibodies
KR20250166188A (ko) Tnfr2 결합 폴리펩타이드 및 이의 용도의 방법
US20240174755A1 (en) Platelet derived growth factor receptor (pdgfr) antibodies, conjugates, compositions, and uses thereof
JP7239987B2 (ja) 薬物送達のための抗体融合タンパク質
EP4480965A1 (en) Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat cns diseases
EA048741B1 (ru) Молекулы, связывающие рецептор трансферрина, их конъюгаты, и их применение
WO2024261333A1 (en) Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat nervous system diseases
CA3270656A1 (en) RAGE RECEPTOR-BINDING MOLECULES, THEIR CONJUGATES AND THEIR USES TO DETECT, PREVENT OR TREAT LUNG DISEASES
AU2024314571A1 (en) Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat muscular diseases

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231024

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241017

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250124

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250217

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250429

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250429

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251209

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260331